Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
AstraZeneca chalked up the largest sales in Japan among 11 foreign mega pharma companies operating in the country in 2021, leapfrogging MSD to claim the title with its record revenue, according to a Jiho tally. Jiho compiled a tally of…
To read the full story
Related Article
- MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
- Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
- Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
- Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Foreign Drug Makers Seeking to Offset Risk in US, European Markets by Driving Growth in “Attractive” Japanese Market
May 23, 2014
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
- Ribomic, Fujifilm to Join Forces on LNP CDMO Services
July 7, 2026
- Toray Unveils Next-Generation Opioid Painkiller Candidate
July 7, 2026
- Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…